Finally, Cramer examined the bull and bear cases for the stock of BioTelemetry, a small-capitalization medical device company known for its heart monitors.
The company made a turnaround in early 2016, delivering consistently strong earnings results and making a series of acquisitions. But the bears struck this month with a scathing report from Off Wall Street, giving BioTelemetry's stock a $21 price target and a sell rating.
"The bearish argument boils down to a pretty basic thesis: They believe the company's cardiac monitoring services division, which made up 80 percent of the business last year, is losing market share. It's just that these declines are being obscured by the company's many recent acquisitions," Cramer said.
But more bullish voices from Lake Street and Dougherty & Co. chimed in, attributing the company's slowing revenue growth to Medicare cuts that will soon be reversed.
Dougherty analysts said they expected BioTelemetry's volumes to grow by the high single-digits for the next few years, recommending the stock and giving it a $40 price target.
"I've got to side with the analysts who've been covering the name for years rather than the naysayers at Off Wall Street," Cramer said. "BioTelemetry had run a great deal, but thanks to the sell-off, I think you can get into the stock at a discounted price. I think it's worth buying, cautiously, of course, because it's for speculation only. It's a small-cap stock, even as the newfound negativity has created what may be an excellent buying opportunity."
In an emailed response to CNBC's request for comment, BioTelemetry President and CEO Joseph Capper outlined his bull case, saying his company's tech-enabled devices are in high demand because they can help cut health costs.
"BioTelemetry's cardiac monitoring sales have been driven by a high performance sales organization that is second to none in the market. We have the most advanced technology, providing the highest diagnostic yield with the quickest turnaround time. We have the most robust I.P. portfolio and more published clinical proof studies than any other company in the market," Capper wrote, using shorthand to refer to BioTelemetry's intellectual property.
Capper added that BioTelemetry is uniquely positioned to benefit from the popularity surge in wearable devices and their connection to health care.
"That being the case, we were quite surprised to see the Off Wall Street piece. This came out of left field and was built around a flawed thesis and inaccurate statements. In short, we think "Off Wall Street" is "off the mark" on this one," the CEO wrote. "Look for BioTelemetry to continue to outpace the market, commercializing the most innovative connected health solutions both in and outside of the cardiac monitoring space. The BEAT goes on!"